The Icahn School of Medicine at Mount Sinai developed the Personal Discovery Process (PDP) methodology over years of clinical research. PDP identifies the precise combination of FDA-approved drugs (including non-cancer drugs) that works optimally on your patient’s specific tumour, mirroring its genetic complexity and increasing the prospects of an efficient treatment while also reducing toxicity and side effects.

Our preferred partner VivanTx is a leading biotech company, based in London, who offer advanced personalised cancer therapeutics to patients worldwide in partnership with patients own oncologists.